Boehringer Ingelheim licenses multiple Dark Antigens® from Enara Bio to develop off-the-shelf immunotherapies for non-small cell lung cancer (NSCLC)
Enara Bio today announces that Boehringer Ingelheim has exercised its option to license a number of cancer antigens discovered and validated through the ongoing collaboration using Enara Bio’s Dark Antigen discovery platform, EDAPT®.
- Enara Bio today announces that Boehringer Ingelheim has exercised its option to license a number of cancer antigens discovered and validated through the ongoing collaboration using Enara Bio’s Dark Antigen discovery platform, EDAPT®.
- Based on the licensed antigens, Boehringer intends to develop novel off-the-shelf vaccines for the treatment of patients with NSCLC.
- Under the collaboration, Enara Bio’s EDAPT platform is being used to discover and validate Dark Antigens in multiple solid tumor types.
- During the antigen validation work package, Enara Bio demonstrated that the licensed antigens have several attractive characteristics as targets for immunotherapies.